Intradermal Running Sutures Feasible for Postexcision Superficial Repair and Optimal Cosmetic Outcomes

Intradermal running sutures for superficial repair after excisions are a feasible means of optimizing cosmetic outcomes, according to a case report.

A case report has found that intradermal running sutures for superficial repair after excisions are a feasible means of optimizing cosmetic outcomes. The findings from the report were published in the Journal of Drugs and Dermatology.

In the report, a total of 2 cases were included and commented on by physicians from New York University. Each report included a patient who had to undergo an excision for skin cancer treatment.

The first case study included a 73-year-old man who was scheduled to undergo Mohs surgery for squamous cell carcinoma of the right temple. A layered linear closure with 5-0 Monocryl interrupted deep sutures as well as 5-0 Monocryl intradermal sutures was used to repair a defect that extended to the fascia. The wound was 3.1 cm at final measurement. Dissolvable sutures were used, negating the need for removal.

A 33-year-old woman with a malignant melanoma on her left shin was included in the second case study. An excision with 5-mm margins resulted in a 1.6×1.4-cm defect, which extended to fascia. A layered linear closure with 3-0 polydioxanone interrupted deep sutures, and a 4-0 Prolene running intradermal suture was used to repair the defect. Sutures were left in place for 2 months until removal.

Related Articles

A limitation of the case report was the inclusion of only 2 patients, which may limit the generalizability of the reported results.

“By using a superficial repair method that minimizes epidermal trauma without compromising structural integrity,” the researchers wrote, “dermatologic surgeons can maximize patient satisfaction while providing excellent medical care.”

Follow @DermAdvisor


Lin RL, Mu EW, Hale EK, et al. Use of a buried intradermal (subcutaneous) running suture for superficial repair to optimize cosmetic outcome. J Drugs Dermatol. 2019;18(5):481-482.